![]() ![]() Tan Yann Chong, Ph.D., Co-Founder of Atreca, Inc., and an A*STAR scholar, will head the Atreca-GIS Joint Laboratory. The ability to analyse these genes is expected to pave the way for more targeted and effective immunotherapies. ![]() These capabilities will include identification of genes for immunoglobulin superfamily members, such as antibodies and T cell receptors (TCRs), as well as other genes in B and T cells that play important roles in directing the body’s immune response towards cancer and pathogens, such as bacteria and viruses. Ltd., this research effort will establish a joint lab at the GIS facility in Singapore’s Biopolis campus to add new capabilities to Atreca’s microfluidic technology for next-generation sequence analysis of expressed genes in single cells. REDWOOD CITY, Calif., and Singapore, Decem– Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, and the Genome Institute of Singapore (GIS), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR), announced today the execution of a research collaboration agreement to advance Atreca’s high-throughput, microfluidic technology for single-cell, sequence-based analyses of human immune responses, critical in the discovery and development of immuno-oncology therapeutics.Ĭo-funded by A*STAR and Atreca, and involving Atreca’s Singapore subsidiary, Atreca Pte. Jointly Funded Laboratory to Advance Atreca’s Microfluidic Single-Cell Sequence Analysis Technology to Aid in Development of Immunotherapeutics Atreca and A*STAR’s Genome Institute of Singapore Establish Joint Laboratory for Immuno-Oncology ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |